


Polymorphism



Polymorphism

It is the phenomenon in which the same chemical substance exhibits different internal crystal packing arrangements.

Polymorphism is an exclusively solid state phenomenon.

Polymorphs have distinct :


- (i) Crystal structures (mutual arrangements of molecules, atoms or ions).
- (ii) Physical and chemical properties.

Polymorphs can often have: different morphologies, solubility, colour, melting or sublimation temperatures, densities, thermal or electrical conductivities and other physical properties.


Early developments

Eilhardt Mitscherlich, in 1820, was the first to recognize polymorphism when he identified different crystal structures for **sodium arsenate phosphate**.

In 1832, **Friedrich Wöhler** and **Justus Liebig** discovered the first example of polymorphism in an organic solid, **benzamide**.




In 1938, **J. M. Robertson** and **Alfred Ubbelohde** used X-ray crystallography and determined the crystal structure of the dimorphs of **resorcinol (1,3-dihydroxybenzene)**.



Some types of polymorphism

Conformational polymorphism


Each of the isolated crystal forms contains a different conformation of the same molecule



Tautomeric polymorphism


Crystal forms of tautomers are often considered to be polymorphs, because the tautomers generally equilibrate in solution at the temperature at which the solid forms are isolated.

Omeprazole




Some interesting phenomena

Concomitant polymorphs



(Form A)

1:1 CHCl_3 :n-hexane
at 296K



**Concomitant mixture of
Forms A and B**
1:1 CHCl_3 :n-hexane
at 278 K

3-acetylcoumarin



Form B

glacial acetic acid
at 296K

Disappearing polymorphs

Crystal forms that fail to reappear after their initial isolation.

Pseudopolymorphs

Crystal forms in which an organic molecule is associated with differing amounts of solvent, say water



Occurrence of Polymorphism

Compounds that yield polymorphs readily.

Naphthazarin, pyrazine-2-carboxamide, thiourea and 2-thiobarbituric acid.


Compounds for which a second crystal form is not known

Benzoic acid, D-glucose, urea and naphthalene

Compounds that will yield new crystal forms provided a lot of experimentation is carried out.

“every compound has different polymorphic forms and the number of forms known for a given compound is proportional to the time and energy spent in research on that compound.”


Walter McCrone , in the 1970s



Thermodynamic and Kinetic factors

In a defined set of temperature and pressure conditions,
The most stable polymorph is called the **thermodynamic form (global energy minimum)**

The other polymorph or polymorphs are termed **kinetic or metastable forms (local minima)**.



A metastable polymorph is thermodynamically unstable but it has a finite existence whose duration depends on its rate of transformation to more stable forms.

Thermodynamic versus Kinetic factors


When a compound exists in various solid state forms or polymorphs, two major issues need to be addressed:

- (i) The relative stabilities and the transformations that can occur between the forms.
- (ii) The time needed for the transformations to reach equilibrium.

Thermodynamics provides information about the first aspect (how far) and kinetics about the second (how fast).


Ostwald's rule of stages

“when leaving an unstable state, a system does not seek out the most stable state, but rather the nearest metastable state which can be reached with least loss of free energy”.



Polymorphism and Intermolecular Interactions

The same functional group and the same synthons
but differences in the overall packing.








Resorcinol

Polymorphism and Intermolecular Interactions



The same functional group and the same synthons but the multiple occurrences of these groups in different and distinctive molecular locations

Pyrazinamide



Polymorphism and Intermolecular Interactions

Different synthons and different packing arrangements.





2,6-Dihydroxybenzoic acid

Methods of Polymorph Characterization

Hot Stage Microscopy

Sample is viewed using some form of optical microscopy while a hot stage is employed to control the temperature of the sample.



Powder X-ray Diffraction

Information obtained about:

- Phases present (peak positions)
- Phase concentration (peak areas) and
- Amorphous content (background hump)

Thermal Analysis

Differential Scanning Calorimetry, DSC

- Phase transition
- Glass transition
- Melting
- Crystallization
- Decomposition

The thermal events result in altering the total heat capacity of the system and this is observed as a peak

Thermogravimetry, TGA

Monitors weight change as a function of temperature


- Useful to characterize solvates, hydrates and host-guest compounds
- Quantifying stoichiometry
- Assessing stability

Properties of Polymorphs

Colour



(1) **R** P-1
mp 106.2 °C
 $\theta = 21.7^\circ$





(2) **Y** P₂₁/c
mp 109.8 °C
 $\theta = 104.7^\circ$



(3) **ON** P₂₁/c
mp 114.8 °C
 $\theta = 52.6^\circ$

Polymorphs of ROY




(4) **OP** P₂₁/c
mp 112.7 °C
 $\theta = 46.1^\circ$




(5) **YN** P-1, mp 99 °C
 $\theta = 104.1^\circ$



(6) **ORP** Pbca
mp 97 °C, $\theta = 39.4^\circ$




(7) **RPL**



(8) **Y04**






(9) **YT04** P₂₁/c
mp 106.9 °C
 $\theta = 112.8^\circ$



(10) **R05**



Properties of Polymorphs

Mechanical Properties



Chemical Reactivity

Polymorphism in Energetic Materials



Polymorphism and the Pharmaceutical Industry

Formulation and Activity: Differences in crystal morphology can affect processing properties like filtering, drying, flow, tableting, rate of dissolution, shelf life and bioavailability.

Legal issue: A mixture of polymorphs is chemically pure but it is not pure in a crystallographic sense because it consists of crystals with different crystal structures.

A drug has both chemical and crystallographic properties that may be independently entitled to patent protection.

Polymorphs and patents



US006894051B1

(12) **United States Patent**
Zimmermann et al.

(10) **Patent No.:** **US 6,894,051 B1**
(45) **Date of Patent:** **May 17, 2005**

(54) **CRYSTAL MODIFICATION OF A
N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS
MANUFACTURE AND ITS USE**

(75) Inventors: **Jürg Zimmermann**, Basel (CH);
Bertrand Sutter, Héisingue (FR); **Hans
Michael Bürger**, Allschwil (CH)

(73) Assignee: **Novartis AG**, Basel (CH)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 311 days.

(21) Appl. No.: **09/463,097**

(22) PCT Filed: **Jul. 16, 1998**

(86) PCT No.: **PCT/EP98/04427**

§ 371 (c)(1),
(2), (4) Date: **Jan. 18, 2000**

(87) PCT Pub. No.: **WO99/03854**

PCT Pub. Date: **Jan. 28, 1999**

(30) **Foreign Application Priority Data**

Jul. 18, 1997 (CH) 1764/97

(51) **Int. Cl.⁷** **A61K 31/506**; C07D 401/14

(52) **U.S. Cl.** **514/252.18**; 544/295

(58) **Field of Search** 544/295; 514/252.18

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,351,832 A 9/1982 Rabbitt et al.
5,521,184 A * 5/1996 Zimmermann 514/252
5,985,893 A * 11/1999 Yu et al. 514/312
6,048,866 A 4/2000 Hutchings et al.

FOREIGN PATENT DOCUMENTS

WO WO 85/00604 2/1985

OTHER PUBLICATIONS

Zimmermann, et al., Potent and Selective Inhibitors of the
Abl-Kinase: Phenylaminopyrimidine (PAP) Derivatives,
Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 2, pp.
187-192 (1997).

Elisabeth Buchdunger, et al., Inhibition of the Abl Protein-
Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylami-
nopyrimidine Derivatives, Cancer Research, pp. 100-104,
Jan. 1, 1996.

Byrn, Stephen et al., "Pharmaceutical Solids: A Strategic
Approach to Regulatory Considerations," Pharmaceutical
Research, vol. 12, No. 7, pp. 945-954 (1995).

Davey, R.J. et al., "Polymorphism in Molecular Crystals:
Stabilization of a Metastable Form by Confirmation Mim-
icry," J. Am. Chem. Soc. 1997, vol. 119, pp. 1767-1772
(1997).

Hollis Showalter H.D. et al., "Small Molecule Inhibitors of
the Platelet-Derived Growth Factor Receptor, the Fibroblast
Growth Factor Receptor, and Src Family Tyrosine Kinases,"
Pharmacol. Ther., vol. 76, No. 1-3, pp. 55-71 (1997).

Myllärniemi Marjukka et al., "Selective Tyrosine Kinase
Inhibitor for the Platelet-Derived Growth Factor Receptor
In Vitro Inhibits Smooth Muscle Cell Proliferation After
Reinjury of Arterial Intima In Vivo," Cardiovascular Drugs
and Therapy, vol. 13, pp. 159-168 (1999).

Radebough, Galen W., "Preformulation," Remington: The
Science and Practice of Pharmacy, 20th Edition, Chapter 83,
pp. 1447-1462 (2000).

* cited by examiner

Primary Examiner—Emily Bernhardt

(74) Attorney, Agent, or Firm—George R. Dohmann

(57)

ABSTRACT

The invention relates to a new crystalline form of the
methanesulfonic acid addition salt of 4-(4-methylpiperazin-
1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-
ylamino]phenyl]benzamide of formula 1, which may be
used for example for tumor therapy.


18 Claims, 2 Drawing Sheets

- Novelty
- Non-obviousness
- Utility

Case Studies from the Pharmaceutical Industry


Ranitidine

Legal issue




Ritonavir

Phase transformation and therapeutic issue




Aspirin

Intergrown crystal domains



Omeprazole

Tautomeric polymorphism



Points to be kept in mind:


Polymorphs are different crystal forms of the same chemical compound. Polymorphism is a solid state phenomenon.

Polymorphs can exhibit different physical and chemical properties.

Competing intermolecular interactions result in dominance of kinetic factors during crystallization.

A trade-off between kinetics and thermodynamics can lead to polymorphism.

Polymorphism occurs frequently in organic solids and notably in drug molecules because they contain flexible functional groups capable of hydrogen bonding.



Viel Glück!